Programmed Death-Ligand 1 Expression in Lung Cancer and its Association with Clinicopathological Characteristics, Tumor Microenvironments, Driver Mutations, and Clinical Outcomes
博士 === 國立臺灣大學 === 病理學研究所 === 106 === Lung cancer is the leading cause of cancer-related death worldwide despite a lot of advances in cancer treatment have been achieved in recent decades. Currently, the treatment strategy for advanced lung cancer has been moved forward from conventional platinum bas...
Main Authors: | Ching-Yao Yang, 楊景堯 |
---|---|
Other Authors: | Yih-Leong Chang |
Format: | Others |
Language: | en_US |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/dv2xp2 |
Similar Items
-
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
by: Claudia Grosse, et al.
Published: (2019-01-01) -
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
by: Haotian Liao, et al.
Published: (2019-09-01) -
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
by: Joon Seon Song, et al.
Published: (2019-10-01) -
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
by: Ji Hye Kim, et al.
Published: (2020-03-01) -
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
by: Huarong Cai, et al.
Published: (2020-06-01)